Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis
- 12 March 2018
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 25 (7) , 934-e70
Abstract
Background and purpose: Nabiximols (Sativex®) is a cannabinoid‐based compound used for the treatment of moderate to severe spasticity in multiple sclerosis (MS). The aim of the study was to investigate the effect of the administration of Nabiximols on blood transcriptome profile of patients with MS and to interpret it in the context of pathways and networks.Methods: Whole‐genome expression profiling was performed in whole blood of 33 subjects with MS at baseline and after 4 weeks of drug treatment. Patients were classified as responders (n = 19) and non‐responders (n = 14). Pathway and network analyses on genes modulated by the drug were performed, followed by in vitro stimulation of peripheral blood mononuclear cells with pro‐inflammatory agents to support the immunomodulatory properties of the drug.Results: Individual effect size was modest; however, we observed a downregulation of several immune‐related pathways after 4 weeks of treatment, which was more pronounced when restricting analyses to responders. Interesting hub molecules functionally related to the immune system emerged from network analysis, including NFKB1, FYN, MAP14 and TP53. The immunomodulatory properties of the drug were confirmed through in vitro assays in peripheral blood mononuclear cells collected from patients with MS.Conclusions: Our findings support the immunomodulatory activity of cannabinoids in patients with MS. Further studies in more specific cell types are needed to refine these results.Keywords
Funding Information
- Urological Research Institute, San Raffaele Hospital, Milan, Italy
This publication has 20 references indexed in Scilit:
- Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trialThe Lancet Neurology, 2013
- Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX NetworkPLOS ONE, 2013
- Fyn Kinase Is Required for Optimal Humoral ResponsesPLOS ONE, 2013
- Identification of Shared Genes and Pathways: A Comparative Study of Multiple Sclerosis Susceptibility, Severity and Response to Interferon Beta TreatmentPLOS ONE, 2013
- Fyn Promotes Th17 Differentiation by Regulating the Kinetics of RORγt and Foxp3 ExpressionThe Journal of Immunology, 2012
- Neuroprotective agents: CannabinoidsClinical Immunology, 2012
- Regulatory mechanisms involved in the control of ubiquitin homeostasisThe Journal of Biochemistry, 2010
- The nuclear signaling of NF-κB: current knowledge, new insights, and future perspectivesCell Research, 2009
- Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-α production by human mononuclear cellsInternational Immunopharmacology, 2002
- Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitroInternational Journal of Immunopharmacology, 1991